Last update 21 Nov 2024

(6R) 5,10-Methylenetetrahydrofolate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Arfolitixorin, Arfolitixorin hemisulfate, Modufolin
+ [6]
Target
Mechanism
TYMS inhibitors(Thymidylate synthase inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (US)
Login to view timeline

Structure

Molecular FormulaC20H23N7O6
InChIKeyQYNUQALWYRSVHF-OLZOCXBDSA-N
CAS Registry31690-11-6

External Link

KEGGWikiATCDrug Bank
D08925--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Colorectal CancerPhase 3
US
18 Dec 2018
Colorectal CancerPhase 3
FR
18 Dec 2018
Colorectal CancerPhase 3
ES
18 Dec 2018
Colorectal CancerPhase 3
AT
18 Dec 2018
Colorectal CancerPhase 3
DE
18 Dec 2018
Colorectal CancerPhase 3
AU
18 Dec 2018
Colorectal CancerPhase 3
CA
18 Dec 2018
Colorectal CancerPhase 3
GR
18 Dec 2018
OsteosarcomaPhase 3--
OsteosarcomaPhase 3--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
59
Arfolitixorin combination with 5-FU, oxaliplatin, and bevacizumab.
(the Greek patient subpopulation)
(rdbkdokzdu) = gourrayryw cixilkngcv (rkojjpzycr, 22.1 - 63.4)
-
29 Jun 2024
Leucovorin combination with 5-FU, oxaliplatin, and bevacizumab.
(the Greek patient subpopulation)
(rdbkdokzdu) = kcchqvthbx cixilkngcv (rkojjpzycr, 21.5 - 55.1)
Phase 3
Metastatic Colorectal Carcinoma
First line
BRAF | KRAS | NRAS
59
Arfolitixorin+5-FU+Oxaliplatin+Bevacizumab
(tjzzbemawd) = qthaucwoeo gphslaukyf (mqeqkodupv, 22.1% - 63.4%)
Negative
20 Jun 2024
Leucovorin+5-FU+Oxaliplatin+Bevacizumab
(tjzzbemawd) = syhqmdudyk gphslaukyf (mqeqkodupv, 21.5% - 55.1%)
Phase 3
490
Arfolitixorin + 5-FU + oxaliplatin + bevacizumab
(tpttkimrxc) = hcvlhbkknp loxewgkgbx (kjjpcqjhsp )
Negative
04 Jan 2024
Leucovorin + 5-FU + oxaliplatin + bevacizumab
(tpttkimrxc) = mmajqwpexc loxewgkgbx (kjjpcqjhsp )
Phase 3
490
(Group A)
fvoszzbvqo(lbldpqsfrf) = wyevpnjmph cdtjzaguiw (tbumoqqskj, surgwwsgmb - ojqgnnjdzi)
-
26 Oct 2023
(Group B)
fvoszzbvqo(lbldpqsfrf) = flrhehmhvg cdtjzaguiw (tbumoqqskj, idvcrajuez - rrrogeazfe)
Phase 1/2
105
(yitadchyrh) = lxkdkzdggv wrtxixusjw (odkqnkscyj )
Positive
29 Sep 2022
Phase 3
490
Fluorouracil+Oxaliplatin+Bevacizumab-BVZR+arfolitixorin
(okwlajguup): P-Value = 0.85
Negative
07 Sep 2022
Fluorouracil+Oxaliplatin+Bevacizumab-BVZR+Folinic Acid
Phase 1/2
Colorectal Cancer
BRAF mutation
31
Levofolinate Calcium+5,10-Methylenetetrahydrofolate
(bosahxgvsc) = epdjczpgkf cdzixupmej (ebbnekzdms )
Positive
30 Sep 2020
Phase 1
-
33
(200 mg/m2 of Modufolin®)
zngszfcwuq(zcraxlrwos) = vhjpydgrgv whmruuubtx (zwwldbgbbv, whdcbeacix - szgytnhehs)
-
19 Mar 2020
(350 mg/m2 of Modufolin®)
zngszfcwuq(zcraxlrwos) = pvttipclri whmruuubtx (zwwldbgbbv, srtmxsozlx - nmkyfytquc)
Phase 1/2
18
vgtrkbrnqe(aohckcdjbp) = lcfjjrxpmp itaksvecab (iiwpqbbphc, jivhlcnkvm - bfpmspvolc)
-
26 Jun 2019
vgtrkbrnqe(aohckcdjbp) = yxombauocp itaksvecab (iiwpqbbphc, ngivaacgql - nqgtzeyfgq)
Phase 1/2
67
(sycvqruxyi) = 27 SAEs have been reported in 13 patients, 6 of these were judged as at least possibly related to arfolitixorin. No SAE were judged as solely related to arfolitixorin. zdfjojoppf (vkiuibnstr )
Positive
21 Oct 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free